PRIM E 100

DESCRIPTION
Methenolone Enanthate 100 is a dihydrotestosterone derived anabolic steroid. Methenolone Enanthate 100 contains methenolone enanthate, a long- acting methenolone ester producing a rapid onset of serum methenolone with a continued duration of action of 5 to 7 days after IM injection. Methenolone Enanthate 100 is moderately anabolic with limited androgenic properties. Methenolone cannot aromatize to estrogen, reducing estrogenic side effects, and has a favorable safety profile among anabolic agents.

INDICATIONS
As an alternate or adjunctive therapy in patients for the promotion of weight gain following weight loss and/or muscular atrophy associated with extensive surgery, chronic infections, long term hospitalization, or severe trauma. To compensate for protein catabolism consequent to corticosteroid therapy.

ADVERSE REACTIONS
Male: Gynecomastia, increased frequency of erections, azoospermia, priapism, oligospermia, prostatic hypertrophy.increased risk of prostate carcinoma.
Skin and Appendages: Hirsutism, pattern baldness and acne, gynecomastia,
Fluid/Electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; rarely, hepatocellular neoplasms, peliosis hepatis, hepatic adenomas, and cholestatic hepatitis.
Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anticoagulant therapy.
Nervous System: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.
Metabolic: Reduced glucose tolerance and inhibition of gonadotropin secretion.
Other: Serum lipid changes, hypercalcaemia, hypertension, oedema, and potentiation ofsleep apnea.

CONTRAINDICATIONS
Patients with diagnosed or suspected carcinoma of the prostate, breast, or testis. Patients with diagnosed or suspected female breast carcinoma with hypercalcemia as androgenic agents may increase osteolytic bone resorption. Women who are pregnant or may become pregnant because of possible masculinization of the fetus. Patients with nephrosis or the nephrotic phase of nephritis. Patients with hypercalcemia. Hypersensitivity to this product or any of its ingredients. Patients with pre-existing cardiac, renal, and/or hepatic disease. Discontinue treatment upon signs of jaundicing or hepatotoxicity.

PRESENTATION
Methenolone Enanthate 100 mg/ml, 10 ml multiple dose vial.

DOSAGE AND ADMINISTRATION
Adult male: 100 – 200 mg injected IM every 3 – 5 days for a duration of 8 to 12 weeks.

STORAGE
Store in a cool dry place between 15 -25°C, Protect from light.